

BMJ Open

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate induced lymphopenia

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2017-016276 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 04-Feb-2017 |
| Complete List of Authors: | Kowalec, Kaarina; University Of British Columbia, Medicine (Neurology) Kingwell, Elaine; University of British Columbia Faculty of Medicine Carruthers, Robert; University Of British Columbia, Medicine (Neurology) Marrie, Ruth; University of Manitoba, Departments of Internal Medicine and Community Health Sciences Bernatsky, Sasha; Research Institute MUHC, Traboulosee, Anthony; University of British Columbia Faculty of Medicine Ross, Colin; University Of British Columbia, Faculty of Pharmaceutical Sciences; B.C. Children's Hospital Research Institute Carleton, Bruce; University of British Columbia; B.C. Children's Hospital Research Institute Tremlett, Helen; University Of British Columbia, Medicine (Neurology) |
| Primary Subject Heading: | Neurology |
| Secondary Subject Heading: | Genetics and genomics, Patient-centred medicine, Pharmacology and therapeutics |
| Keywords: | CLINICAL PHARMACOLOGY, Multiple sclerosis < NEUROLOGY, Adverse events < THERAPEUTICS, GENETICS |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **Application of pharmacogenomics to investigate adverse drug reactions to the disease-**
4 **modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl**
5 **fumarate induced lymphopenia**
6
7
8
9
10

11
12 Kaarina Kowalec¹, Elaine Kingwell¹, Robert Carruthers¹, Ruth Ann Marrie², Sasha Bernatsky³,
13 Anthony Traboulsee¹, Colin J.D. Ross^{4,5}, Bruce Carleton^{5,6}, Helen Tremlett^{1*}
14
15

16
17 ¹Faculty of Medicine, Division of Neurology and Djavad Mowafaghian Centre for Brain Health,
18 University of British Columbia, Vancouver, Canada

19
20 ²Departments of Internal Medicine and Community Health Sciences, Max Rady College of
21 Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada

22
23 ³Division of Rheumatology, McGill University, Montreal, Canada

24
25 ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

26
27 ⁵B.C. Children's Hospital Research Institute, Vancouver, Canada

28
29 ⁶Faculty of Medicine, Department of Pediatrics, University of British Columbia, Vancouver,
30 Canada
31

32
33
34
35 *Corresponding author:

36
37 Email: helen.tremlett@ubc.ca (HT)
38
39
40
41
42
43
44

45 **Short title:** Pharmacogenomic biomarkers of adverse drug reactions from multiple sclerosis
46 therapies: A study protocol
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Adverse drug reactions are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutic areas, including HIV infection, and oncology. Dimethyl fumarate is a licensed disease modifying therapy for the treatment of multiple sclerosis (MS). The use of dimethyl fumarate in MS has been associated with a severe reduction in lymphocyte counts and reports of progressive multifocal leukoencephalopathy. Here, we outline the protocol for a case-control study to investigate dimethyl fumarate-induced lymphopenia. The ultimate goal is to create an efficient and adaptable approach towards the investigation and discovery of genomic markers that could assist in mitigating adverse drug reactions in MS.

Methods and Analysis: The population sample will comprise dimethyl fumarate-exposed MS patients, with cases representing those who developed lymphopenia and controls who did not. DNA genotyping will take place using a high-throughput genome-wide array. Fine mapping and imputation will be performed to focus in on the potentially causal variants associated with lymphopenia. Multivariable logistic regression will be used to compare genotype and allele frequencies between the cases and the controls, with consideration of potential confounders. The association threshold will be set at $p < 1.0 \times 10^{-5}$ for the discovery genomic association analyses, to select variants for replication.

Ethics and Dissemination: Ethics approval has been obtained from the respective Research Ethics Board, which includes written informed consent. Findings will be disseminated widely, including at scientific conferences, via podcasts (targeted at both healthcare professionals as well as patients and the wider community), through patient engagement and other outreach community events, written lay summaries for all participants, and formal publication in peer-reviewed scientific journals.

Strengths

- This study aims to minimize adverse drug reactions, specifically dimethyl fumarate induced lymphopenia in multiple sclerosis, through the discovery of pharmacogenomic biomarkers
- This protocol is easily adaptable to the search for genomic markers of other adverse drug reactions associated with the multiple sclerosis disease modifying therapies
- We propose to investigate a phenotype that is based on an objective laboratory measurement (the absolute lymphocyte counts), to facilitate replication in future studies.

Limitations

- Results may be limited to adults with multiple sclerosis of specific genetic ancestries.
- The scarcity of literature on the genetic basis of drug-induced lymphopenia, combined with dimethyl fumarate's undefined mechanism of action, means that a hypothesis-free genome-wide approach, rather than a targeted candidate gene investigation, is preferred to identify any pharmacogenomic biomarkers of the adverse drug reaction.
- Functional investigation of any identified genetic variants associated with the adverse drug reaction with *in vivo* or *in vitro* models are beyond the scope of the current protocol, but will be developed if a genetic target is discovered.

Introduction

1
2
3 Adverse drug reactions (ADRs) are a serious public health issue, representing the 4th to 6th
4 leading cause of death in American hospitals (1), and were reported to be responsible for an
5 estimated 1 out of every 15 hospital admissions by authors of a United Kingdom-based study
6 (2). Over the last decade, the disease modifying therapy options for multiple sclerosis (MS)
7 have increased, with over ten different products now available. However, these treatments carry
8 some serious safety concerns. Possibly the most studied and monitored ADR to an MS disease
9 modifying therapy has been the fatal, or severely debilitating opportunistic infection, progressive
10 multifocal leukoencephalopathy (PML), which is caused by reactivation of the John Cunningham
11 virus. This ADR has primarily been associated with natalizumab, but more recently, case reports
12 of PML with other MS disease modifying therapies, including dimethyl fumarate (DMF), have
13 emerged (3, 4). A severe reduction in lymphocytes (Grade 3) has been associated with the
14 subsequent occurrence of PML (3). Given the relatively high proportion of DMF exposed
15 individuals experiencing reductions in their lymphocyte counts, the potential for PML occurring
16 during DMF exposure is a significant concern. During the 96-week pivotal clinical trial, 1 in 20
17 (5%) DMF-treated patients experienced severe, 'Grade 3' lymphopenia (5) (defined as absolute
18 lymphocyte counts $<0.5-0.2 \times 10^9/L$ or $<500-200/mm^3$ by the Common Terminology Criteria of
19 Adverse Events (6)). While a similar proportion of DMF-exposed patients (5.9%) experienced
20 Grade 3 lymphopenia in a subsequent post-marketing study, this actually occurred over a
21 shorter observation period (44 weeks), and 20% of those aged over 55 years were affected (7).

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Currently, it is challenging to predict serious ADRs to the MS disease modifying therapies, using clinical or demographic features. Validated pharmacogenomic biomarkers can predict an individual's ADR risk and offer an important means of facilitating appropriate drug selection, dose initiation or tailored safety monitoring (8). Here, we focus on DMF-induced lymphopenia because of its high clinical importance in MS given its previous association with PML. To the

1
2
3 best of our knowledge, DMF-induced lymphopenia has not been examined in the context of
4
5 pharmacogenomics.
6
7
8

9 10 **Study aims**

11 This protocol outlines an efficient and adaptable case-control study designed to discover
12
13 pharmacogenomic markers that could be used to tailor therapy and thereby reduce the
14
15 occurrence of DMF-induced lymphopenia. Specifically, utilizing a genome-wide association
16
17 approach, we will investigate whether DMF-induced lymphopenia can be genotypically
18
19 predicted.
20
21
22
23

24 25 **Methods**

26 27 **Study patients**

28 We developed an efficient and comprehensive method to identify relevant biomarkers of drug
29
30 harm through the Canadian Pharmacogenomics Network for Drug Safety, as previously
31
32 described (9). The source population for the discovery sample will comprise adult patients (≥ 18
33
34 years old) who were seen at the Djavad Mowafaghian Centre for Brain Health MS clinic, located
35
36 at the University of British Columbia, Vancouver, Canada, diagnosed with relapsing-onset MS
37
38 (based on the internationally recognized criteria current at the time of diagnosis (10-13)) and
39
40 have documented exposure to DMF. Participants will be recruited 2016-2018. Cases and
41
42 controls will be drawn from this source population; cases will be defined as patients who
43
44 experience Grade 3 lymphopenia as documented on at least one result from a laboratory test
45
46 conducted during DMF exposure (Table 1). Eligible controls will be patients who are 'drug
47
48 tolerant' as determined by a minimum of one-year exposure to DMF and normal lymphocyte
49
50 counts as documented on all available results of laboratory test conducted during DMF
51
52 exposure (Table 1). Each patient's medical record will be extensively reviewed to collect clinical
53
54 and demographic information including sex, date of birth, laboratory test results (date, numeric
55
56
57
58
59
60

result, units and normal range assigned by the testing laboratory), prior disease modifying therapy exposure, and concomitant medication exposure (dates of initiation and cessation, drug name, dose, frequency, when available). Data will be collated by means of a structured study-specific form. A questionnaire will be administered to all cases and controls to obtain additional information not always available in the medical records: infections requiring treatment with a systemic antimicrobial agent, comorbid conditions, and patient height and weight (to calculate body mass index). These factors may represent contributing causes of lymphopenia or potential confounders of the relationship between a putative genomic marker and the ADR. A validated ADR causality assessment tool, the Naranjo scale (14), will be employed to assist with the exclusion of competing etiologies. A one-year time frame is anticipated for patient recruitment for inclusion in a 'discovery stage' analyses. A replication cohort will be identified and recruited in the event any genomic variants reach the pre-determined statistical threshold in the discovery stage.

Table 1: Summary of the adverse drug reaction, severity and definitions used to select the multiple sclerosis cases and drug tolerant controls

| ADR | ADR Severity ^a | Case definition | Control definition |
|-------------------------|--|---|--|
| DMF-induced lymphopenia | Grade 3: Defined using the CTCAE as a 'severe or medically significant event' | 1. Normal baseline ^b ALC (≤ 6 months prior to DMF initiation) <i>and</i> 2. ≥ 1 laboratory test result with ALC $< 500\text{-}200/\text{mm}^3$ or $< 0.5\text{-}0.2 \times 10^9/\text{L}$ during DMF exposure (6, 7) | 1. Normal baseline ^b ALC (≤ 6 months prior to DMF initiation) <i>and</i> 2. Exposure to DMF for ≥ 1 year (5) <i>and</i> 3. ≥ 1 ALC test performed during treatment, with all results within the normal range ^b |

ADR: Adverse drug reaction, DMF: dimethyl fumarate, ALC: absolute lymphocyte counts.

^aGraded by the Common Terminology Criteria for Adverse Events (CTCAE) (v4.03) (6).

^bNormal range defined by the testing laboratory.

We expect to recruit 156 patients (52 cases and 104 controls) to have sufficient power (80%) to identify a genomic variant (minor allele frequency > 0.15) with a clinically significant effect size (odds ratio > 5.0) and the National Human Genome Research Institute genome wide

1
2
3 association study catalog threshold of $p < 1.0 \times 10^{-5}$ (15). Sample size estimation was performed
4
5 using Quanto (v.1.2.4) (16).
6
7
8

9 10 **Ethics, consent and permissions**

11 The University of British Columbia Clinical Research Ethics Board, and the Vancouver Coastal
12 Health Research Institute have approved this study protocol (H16-01927), which includes
13
14 written informed consent from all participants.
15
16
17
18

19 20 **Collection of saliva, genotyping and fine mapping**

21 A saliva sample will be obtained from patients, either during their clinic visit or collected at home
22 and returned via mail, with Oragene[®] collection tubes (DNA Genotek, Ottawa, Canada). DNA
23
24 will be extracted from saliva with the QIAmp DNA purification system (Qiagen, Hilden,
25
26 Germany) and subsequently quantified using the Quanti-iT PicoGreen assay (Invitrogen,
27
28 Carlsbad, USA). DNA samples will be stored at -20°C until all samples have been collected.
29
30
31
32
33

34
35 Samples will be processed with the Illumina Tecan Freedom EVO 150 and scanned on the
36
37 Illumina HiScan System (Illumina, San Diego, USA). Every set of 96 samples will include a
38
39 negative (1x Tris-EDTA buffer) and positive control. Samples will be genotyped using a
40
41 genome-wide genotyping array. We propose a hypothesis-free, genome-wide approach for the
42
43 identification of potential pharmacogenomic biomarkers related to this ADR. Rationale for this
44
45 approach stems from the dearth of literature on the genetic basis of drug-induced lymphopenia,
46
47 including no relevant pharmacogenomic studies with DMF. Moreover, as the exact mechanism
48
49 of DMF-lymphopenia is undefined, it is impractical to predict which genes are involved in this
50
51 ADR. In the event that validated pharmacogenomic markers of drug-induced lymphopenia are
52
53 available at the time of genotyping, we will consider these in the current study.
54
55
56
57
58
59
60

1
2
3
4
5
6 For quality control purposes, genomic variants will be excluded with call rates <90%, a minor
7
8 allele frequency <1%, or those deviating from the Hardy-Weinberg equilibrium genotype
9
10 distribution ($p < 1.0 \times 10^{-5}$ in controls). Individual samples will also be excluded with call rates
11
12 <95%, and those cryptically related to other samples, or if the individual's sex according to the
13
14 genotyping is discordant with that recorded in the medical records.
15
16

17
18
19
20
21 We will perform linkage disequilibrium analyses (r^2 and D') using the 1000 Genomes CEU
22
23 population (Utah residents with Northern and Western European ancestry)
24
25 (<http://www.1000genomes.org>) and other populations, as appropriate. Haplotypes and
26
27 haplotype blocks will be calculated using CEU 1000 Genomes population as described (17).
28
29 Haplotype analyses will be implemented using Golden Helix SNP and Variation Suite (v.8.4,
30
31 Bozeman, USA).
32
33

34
35
36
37
38 Fine mapping and imputation will be performed to uncover putative causal variants. We will
39
40 perform genetic fine mapping analysis by genotype imputation of additional SNPs not present
41
42 on the genotyping platform using BEAGLE 4.0 with LD and haplotype information from 1000
43
44 Genomes (Phase 3) as the reference population (18, 19). We will impute additional variants on
45
46 the chromosome region (+/- 500 kb) containing any significant variants identified during the
47
48 discovery phase. Any significant variants within the imputed region will be assessed by means
49
50 of the Combined Annotation Dependent Depletion (CADD) framework (20) and corroboratory
51
52 evidence regarding the function of any associated variants will be explored from the literature.
53
54 The quality control metric (BEAGLE allelic R^2) will be calculated for all imputed SNPs, and will
55
56 include SNPs with an $R^2 \geq 0.5$ for analysis.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Given the association between specific human leukocyte antigen (HLA) alleles and a first-line disease modifying therapy for MS, interferon-beta (21-23), we will also investigate whether an association between DMF-induced lymphopenia and specific HLA alleles exist. We will directly type *HLA-DRB1*15:01*, in addition to utilizing the HLA-specific imputation program, SNP2HLA (24), to determine the specific HLA alleles of the individuals.

The genotyping calls of any significant variants from the genome-wide array, or those prioritized by fine mapping, will be validated by TaqMan[®] genotyping assay (ThermoFisher Scientific, Waltham, USA).

Replication of findings

We will seek to replicate any significant variants reaching the pre-determined threshold in an independent replication cohort within the Canadian Network of MS Clinics (www.cnmsc.ca). All participant inclusion and exclusion criteria will match that of the criteria utilized in the discovery cohort.

Data management

The principal investigator (HT) and the study team will manage all the patient data for this study. All data will be stored on a secure server, on a password-protected computer, located at the University of British Columbia, Faculty of Medicine.

Statistical analyses

Clinical and demographic factors will be compared between cases and controls. Categorical variables will be summarized by frequency (percent) and analyzed using either parametric (Chi-

1
2
3 square test) or non-parametric tests (Fisher's exact test). Continuous variables will be
4
5 summarized by describing mean (standard deviation) or median (interquartile range) and
6
7 analyzed using the appropriate parametric (unpaired Student *t*-test) or non-parametric test
8
9 (Mann-Whitney *U* test). Genomic ancestry will be ascertained by means of principal
10
11 components analysis (EIGENSTRAT method) (25) utilizing the genotyping data and the 1000
12
13 Genomes Project reference data (18).
14

15
16
17
18 Differences in genotype and allele frequencies between cases and controls will be tested using
19
20 logistic regression, with DMF-induced lymphopenia as the outcome. The logistic regression
21
22 model will use an additive genetic model to identify associations since this model has been used
23
24 previously to detect significant genetic differences associated with cases of adverse drug
25
26 reactions (26, 27). In addition, the additive model is the most common genetic association test
27
28 in which the underlying genetic model is unknown (28). The regression analyses will be
29
30 adjusted for any relevant characteristics, such as sex, age, genetic ancestry or previous disease
31
32 modifying therapy exposure (7). To examine evidence of additional genetic associations with the
33
34 adverse drug reaction in the imputed region, the same analysis and models utilized in the initial
35
36 analysis will be applied.
37
38
39

40
41
42 For the genomic association analyses, the threshold to indicate variants that will require
43
44 replication will be $p < 1.0 \times 10^{-5}$ (15). During the replication stage of the genomic analysis, we will
45
46 employ a Bonferroni corrected $p < 0.05/n$ (n = number of significant SNPs from the discovery
47
48 phase). We will include any genetic variants reaching the predetermined significance threshold
49
50 into the logistic regression model and adjust for potential confounders. Golden Helix SNP and
51
52 Variation Suite (v.8.4, Bozeman, USA) and IBM SPSS (v.23, Armonk, USA) will be used to
53
54 conduct the statistical analyses. Visual plots (Manhattan and regional association plots) will be
55
56 generated using Golden Helix and LocusZoom (29).
57
58
59
60

Dissemination

Findings will be disseminated via various avenues, including at scientific conferences, via podcasts (targeted to healthcare professionals, patients and the general public), through patient engagement and other outreach events, written lay summaries for all participants, and formal publication in peer-reviewed scientific journals.

Discussion

ADRs present a significant burden to global health care systems. In the United Kingdom alone, ADRs were estimated to cost the National Health Service £466 million (US\$847 million) in 2002 (2). A more recent Swedish study reported the overall annual direct cost of adverse drug events as US\$21 million per 100,000 inhabitants, including the costs of diagnosing, monitoring or treating the events (30). Neither the financial costs nor the morbidity and mortality rates associated with ADRs to the MS disease modifying therapies are fully known as yet; this is despite the ubiquitous use of these therapies. Given the clinical importance of ADRs, it is highly desirable to minimize their occurrence. One approach to minimizing ADRs is through the discovery and implementation of pharmacogenomic biomarkers; an example of the utility of this approach is demonstrated by the now commonly accepted clinical practice of testing for the *HLA-B*57:01* allele in HIV-infected persons to prevent abacavir induced hypersensitivity (31).

Our protocol, which is aimed here at discovering biomarkers associated with DMF-lymphopenia, is readily adaptable to the search for genomic markers of other ADRs associated with the MS disease modifying therapies (e.g. alemtuzumab induced immune thrombocytopenia). There are several key considerations when conducting pharmacogenomic studies of serious ADRs (32). Arguably one of the most important is the thorough phenotyping of cases and controls, as poor

1
2
3 characterization contributes to the lack of replication between studies (8). We have proposed to
4 investigate a phenotype that is based on an objective laboratory measurement (the absolute
5 lymphocyte counts); this may facilitate replication in future studies. A genome-wide, hypothesis-
6 free method, as proposed here, could be considered an ideal approach to identify
7
8 pharmacogenomic biomarkers associated with an ADR because the mechanism of action of
9
10 DMF is unclear (33), making it difficult to pre-specify or hypothesize which genes might be
11
12 involved in the ADR. Other important considerations when designing pharmacogenomic studies
13
14 of serious adverse drug reactions include the appropriate sourcing of a replication cohort; a
15
16 multi-center collaboration is being sought through the Canadian Network of MS clinics
17
18 (www.cnmsc.ca); this has been successfully achieved in a prior study (34). Such collaboration
19
20 can also serve to demonstrate the generalizability of findings across multiple sites.
21
22
23
24
25
26
27
28

29 The disease modifying therapy options that are available for people with MS have increased
30 substantially over the last decade. This rise in therapeutic choices has provided many benefits,
31 including non-injectable options and, for the newer therapies, increased efficacy over the
32 previous MS disease modifying therapies (5, 35, 36). However, serious ADRs are associated
33 with these newer disease modifying therapies, and there are currently few means of predicting
34 whom they might affect. If pharmacogenomic biomarkers can be identified by the methods
35 proposed here, this would offer a 'precision medicine' approach to managing MS drug
36 treatments by facilitating choice of optimal disease modifying therapy or by tailoring safety
37 monitoring. Ultimately, the incorporation of pharmacogenomic biomarkers into the complex
38 therapeutic decision-making process would benefit MS patients and healthcare providers.
39
40
41
42
43
44
45
46
47
48
49
50

51
52
53 Acknowledgements: Not applicable.

54 Author Contributions: KK, EK and HT contributed to the concept and design of the study, and
55 drafting of the article. All authors reviewed, commented and approved the final manuscript.
56
57
58
59
60

1
2
3 Funding: This work was supported by the Canadian Institutes of Health Research (CIHR) –
4 Drug Safety and Effectiveness Network (British Columbia site PI: Tremlett).

5
6 Competing interests: There are no conflicts related to this work. KK, EK, RC, and SB have no
7 competing interests to declare. AT has received grant support from Hoffman la Roche and
8 Sanofi Genzyme; steering committee membership for Hoffman la Roche; consultancy for
9 Biogen, Chugai, EMD Serono, Hoffman la Roche, Medimmune, Sanofi Genzyme, and Teva
10 Neuroscience. RAM has conducted clinical trials for Sanofi-Aventis and receives research
11 funding from CIHR, the National MS Society, the MS Society of Canada, the MS Scientific
12 Research Foundation, Research Manitoba, and the Waugh Family Chair in Multiple Sclerosis.
13 CJDR receives funding support from the Canadian Institutes of Health Research, Canadian
14 Foundation for Innovation, Canadian Hearing Foundation, BC Children's Hospital Foundation,
15 BC Children's Hospital Research Canadian Gene Cure Foundation, Teva Pharmaceutical
16 Industries Inc., Genome BC, and the CIHR Drug Safety & Effectiveness Network. BC currently
17 receives research funding from the Canadian Institutes of Health Research, Genome Canada,
18 Genome British Columbia and BC Children's Hospital Research (Vancouver, Canada) and has
19 previously held matching funds support for Genome Canada funding from Pfizer Canada
20 (unrestricted). HT has received speaker honoraria and/or travel expenses to attend conferences
21 from the Consortium of MS Centres (2013), National MS Society (2012, 2014, 2016), Teva
22 Pharmaceuticals (2011), ECTRIMS (2011-2016), UK MS Trust (2011), the Chesapeake Health
23 Education Program, US Veterans Affairs (2012), Novartis Canada (2012), Biogen Idec (2014),
24 AAN (2013-2016). All speaker honoraria are either declined or donated to an MS charity or to an
25 unrestricted grant for use by her research group.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 References

- 50
51 1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients:
52 a meta-analysis of prospective studies. *JAMA* 1998;279(15):1200-5.
53
54 2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions
55 as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ*. 2004;329(7456):15-9.
56
57
58
59
60

3. Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. *N Engl J Med*. 2015;372(15):1476-8.
4. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. *N Engl J Med*. 2013;368(17):1658-9.
5. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. *N Engl J Med*. 2012;367(12):1087-97.
6. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) 2010. Accessed 1 July 2016. Version 4.03. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
7. Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. *Mult Scler J- Exp, Transl Clin*. 2015;1.
8. Pirmohamed M. Pharmacogenetics: past, present and future. *Drug discovery today*. 2011;16(19-20):852-61.
9. Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, et al. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. *Pharmacoepidemiol Drug Saf*. 2009;18(8):713-21.
10. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann Neurol*. 1983;13(3):227-31.
11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol*. 2001;50(1):121-7.
12. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol*. 2005;58(6):840-6.
13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*. 2011;69(2):292-302.
14. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther*. 1981;30(2):239-45.
15. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nuc Acids Res*. 2014;42(Database issue):D1001-6.
16. Gauderman WJ MJ. QUANTO version 1.2.4 2006. Accessed 1 April 2016. Available from: <http://hydra.usc.edu/gxe>.
17. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. *Science*. 2002;296(5576):2225-9.
18. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. *Nature*. 2015;526(7571):68-74.
19. Browning BL, Browning SR. Genotype Imputation with Millions of Reference Samples. *Am J Huma Genet*. 2016;98(1):116-26.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet.* 2014;46(3):310-5.
21. Mazdeh M, Taheri M, Sayad A, Bahram S, Omrani MD, Movafagh A, et al. HLA genes as modifiers of response to IFN-beta-1a therapy in relapsing-remitting multiple sclerosis. *Pharmacogenomics.* 2016;17(5):489-98.
22. Nunez C, Cenit MC, Alvarez-Lafuente R, Rio J, Fernandez-Arquero M, Arroyo R, et al. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-beta therapy in multiple sclerosis. *J Med Genet.* 2014;51(6):395-400.
23. Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima I, Brynedal B, et al. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. *PloS one.* 2014;9(3):e90479.
24. Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS, et al. Imputing amino acid polymorphisms in human leukocyte antigens. *PloS one.* 2013;8(6):e64683.
25. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet.* 2006;38(8):904-9.
26. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet.* 2009;41(7):816-9.
27. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology.* 2011;141(1):338-47.
28. Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT. Basic statistical analysis in genetic case-control studies. *Nat Protocols.* 2011;6(2):121-33.
29. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics.* 2010;26(18):2336-7.
30. Gyllensten H, Hakkarainen KM, Hagg S, Carlsten A, Petzold M, Rehnberg C, et al. Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adults. *PloS one.* 2014;9(3):e92061.
31. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med.* 2008;358(6):568-79.
32. Kowalec K, Carleton B, Tremlett H. The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. *Mult Scl Rel Dis.* 2013;2(3):183-92.
33. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain.* 2011;134(Pt 3):678-92.
34. Kowalec K, Wright GEB, Drögemöller B, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida E, et al. Genome-wide scan identifies association between an interferon regulatory factor-related variant and interferon-beta induced liver injury in multiple sclerosis patients. *Mult Scler J.* 2016;22(S3):828-83.

- 1
2
3 35. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or
4 intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med.* 2010;362(5):402-15.
5
6 36. Vermersch P, Czonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al.
7 Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a
8 randomised, controlled phase 3 trial. *Mult Scler.* 2014;20(6):705-16.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate induced lymphopenia

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2017-016276.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 18-Apr-2017 |
| Complete List of Authors: | Kowalec, Kaarina; University Of British Columbia, Medicine (Neurology) Kingwell, Elaine; University of British Columbia Faculty of Medicine Carruthers, Robert; University Of British Columbia, Medicine (Neurology) Marrie, Ruth; University of Manitoba, Departments of Internal Medicine and Community Health Sciences Bernatsky, Sasha; Research Institute MUHC, Traboulosee, Anthony; University of British Columbia Faculty of Medicine Ross, Colin; University Of British Columbia, Faculty of Pharmaceutical Sciences; B.C. Children's Hospital Research Institute Carleton, Bruce; University of British Columbia; B.C. Children's Hospital Research Institute Tremlett, Helen; University Of British Columbia, Medicine (Neurology) |
| Primary Subject Heading: | Neurology |
| Secondary Subject Heading: | Genetics and genomics, Patient-centred medicine, Pharmacology and therapeutics |
| Keywords: | CLINICAL PHARMACOLOGY, Multiple sclerosis < NEUROLOGY, Adverse events < THERAPEUTICS, GENETICS |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **Application of pharmacogenomics to investigate adverse drug reactions to the disease-**
4 **modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl**
5 **fumarate induced lymphopenia**
6
7
8
9
10

11
12 Kaarina Kowalec¹, Elaine Kingwell¹, Robert Carruthers¹, Ruth Ann Marrie², Sasha Bernatsky³,
13 Anthony Traboulee¹, Colin J.D. Ross^{4,5}, Bruce Carleton^{5,6}, Helen Tremlett^{1*}
14
15

16
17 ¹Faculty of Medicine, Division of Neurology and Djavad Mowafaghian Centre for Brain Health,
18 University of British Columbia, Vancouver, Canada
19

20 ²Departments of Internal Medicine and Community Health Sciences, Max Rady College of
21 Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
22

23 ³Division of Rheumatology, McGill University, Montreal, Canada
24

25 ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
26

27 ⁵B.C. Children's Hospital Research Institute, Vancouver, Canada
28

29 ⁶Faculty of Medicine, Department of Pediatrics, University of British Columbia, Vancouver,
30 Canada
31

32
33
34 *Corresponding author:
35

36 Email: helen.tremlett@ubc.ca (HT)
37
38
39
40
41
42

43 **Short title:** Pharmacogenomic biomarkers of adverse drug reactions from multiple sclerosis
44 therapies: A study protocol
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Adverse drug reactions are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutic areas, including HIV infection, and oncology. Dimethyl fumarate is a licensed disease modifying therapy for the treatment of multiple sclerosis (MS). The use of dimethyl fumarate in MS has been associated with a severe reduction in lymphocyte counts and reports of progressive multifocal leukoencephalopathy. Here, we outline the protocol for a case-control study designed to discover genomic variants associated with dimethyl fumarate-induced lymphopenia. The ultimate goal is to replicate these findings and create an efficient and adaptable approach towards the identification of genomic markers that could assist in mitigating adverse drug reactions in MS.

Methods and Analysis: The population sample will comprise dimethyl fumarate-exposed MS patients, with cases representing those who developed lymphopenia and controls who did not. DNA genotyping will take place using a high-throughput genome-wide array. Fine mapping and imputation will be performed to focus in on the potentially causal variants associated with lymphopenia. Multivariable logistic regression will be used to compare genotype and allele frequencies between the cases and the controls, with consideration of potential confounders. The association threshold will be set at $p < 1.0 \times 10^{-5}$ for the discovery genomic association analyses, to select variants for replication.

Ethics and Dissemination: Ethics approval has been obtained from the respective Research Ethics Board, which includes written informed consent. Findings will be disseminated widely, including at scientific conferences, via podcasts (targeted at both healthcare professionals as well as patients and the wider community), through patient engagement and other outreach community events, written lay summaries for all participants, and formal publication in peer-reviewed scientific journals.

Strengths

- This study aims to minimize adverse drug reactions, specifically dimethyl fumarate induced lymphopenia in multiple sclerosis, through the discovery of pharmacogenomic biomarkers
- This protocol is easily adaptable to the search for genomic markers of other adverse drug reactions associated with the multiple sclerosis disease modifying therapies
- We propose to investigate a phenotype that is based on an objective laboratory measurement (the absolute lymphocyte counts), to facilitate replication in future studies.

Limitations

- Results may be limited to adults with multiple sclerosis of specific genetic ancestries.
- The scarcity of literature on the genetic basis of drug-induced lymphopenia, combined with dimethyl fumarate's undefined mechanism of action, means that a hypothesis-free genome-wide approach, rather than a targeted candidate gene investigation, is preferred to identify any pharmacogenomic biomarkers of the adverse drug reaction.
- Functional investigation of any identified genetic variants associated with the adverse drug reaction with *in vivo* or *in vitro* models are beyond the scope of the current protocol, but will be developed if a genetic target is discovered.

Introduction

Adverse drug reactions (ADRs) are a serious public health issue, representing the 4th to 6th leading cause of death in American hospitals (1), and were reported to be responsible for an estimated 1 out of every 15 hospital admissions by authors of a United Kingdom-based study (2). Over the last decade, the disease modifying therapy options for multiple sclerosis (MS) have increased, with over ten different products now available. However, these treatments carry some serious safety concerns. Possibly the most studied and monitored ADR to an MS disease modifying therapy has been the fatal, or severely debilitating opportunistic infection, progressive multifocal leukoencephalopathy (PML), which is caused by reactivation of the John Cunningham virus. This ADR has primarily been associated with natalizumab, but more recently, case reports of PML with other MS disease modifying therapies, including dimethyl fumarate (DMF), have emerged (3, 4). A severe reduction in lymphocytes (Grade 3) has been associated with the subsequent occurrence of PML (3). During the 96-week pivotal clinical trial, 1 in 20 (5%) DMF-treated patients experienced severe, 'Grade 3' lymphopenia (5) (defined as absolute lymphocyte counts $<0.5-0.2 \times 10^9/L$ or $<500-200/mm^3$ by the Common Terminology Criteria of Adverse Events (6)). A similar proportion of DMF-exposed patients (5.9%) experienced Grade 3 lymphopenia in a subsequent post-marketing study, although this actually occurred over a shorter observation period (44 weeks), with 20% of those aged over 55 years affected (7). The potential for a fatal or severely disabling ADR such as PML occurring during DMF exposure is a significant concern, given that DMF exposed individuals can experience a severe reduction in their lymphocyte counts.

Currently, it is challenging to predict serious ADRs to the MS disease modifying therapies, using clinical or demographic features. Validated pharmacogenomic biomarkers can predict an individual's ADR risk and offer an important means of facilitating appropriate drug selection, dose initiation or tailored safety monitoring (8). Here, we focus on DMF-induced lymphopenia

1
2
3 because of its high clinical importance in MS given its previous association with PML. To the
4 best of our knowledge, DMF-induced lymphopenia has not been examined in the context of
5 pharmacogenomics.
6
7
8
9

10 11 **Study aims**

12 This protocol outlines an efficient and adaptable case-control study designed to discover
13 pharmacogenomic markers that could be used to tailor therapy and thereby reduce the
14 occurrence of DMF-induced lymphopenia. Specifically, utilizing a genome-wide association
15 approach, we will investigate whether DMF-induced lymphopenia can be genotypically
16 predicted.
17
18
19
20
21
22
23
24
25

26 **Methods**

27 **Study patients**

28 We developed an efficient and comprehensive method to identify relevant biomarkers of drug
29 harm through the Canadian Pharmacogenomics Network for Drug Safety, as previously
30 described (9). The source population for the discovery sample will comprise adult patients (≥ 18
31 years old) who were seen at the Djavad Mowafaghian Centre for Brain Health MS clinic, located
32 at the University of British Columbia, Vancouver, Canada, diagnosed with relapsing-onset MS
33 (based on the internationally recognized criteria current at the time of diagnosis (10-13)) and
34 have documented exposure to DMF. Participants will be recruited 2016-2018. Cases and
35 controls will be drawn from this source population; cases will be defined as patients who
36 experience Grade 3 lymphopenia as documented on at least one result from a laboratory test
37 conducted during DMF exposure (Table 1). Eligible controls will be patients who are 'drug
38 tolerant' as determined by a minimum of one-year exposure to DMF and normal lymphocyte
39 counts as documented on all available results of laboratory test conducted during DMF
40 exposure (Table 1). Each patient's medical record will be extensively reviewed to collect clinical
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

and demographic information including sex, date of birth, laboratory test results (date, numeric result, units and normal range assigned by the testing laboratory), prior disease modifying therapy exposure, and concomitant medication exposure (dates of initiation and cessation, drug name, dose, frequency, when available). Data will be collated by means of a structured study-specific form. A questionnaire will be administered to all cases and controls to obtain additional information not always available in the medical records: infections requiring treatment with a systemic antimicrobial agent, comorbid conditions, and patient height and weight (to calculate body mass index). These factors may represent contributing causes of lymphopenia or potential confounders of the relationship between a putative genomic marker and the ADR. A validated ADR causality assessment tool, the Naranjo scale (14), will be employed to assist with the exclusion of competing etiologies. A one-year time frame is anticipated for patient recruitment for inclusion in these 'discovery stage' analyses. Following the discovery of any genomic variants that reach the pre-determined statistical threshold of association with the ADR, a replication cohort will be identified and recruited.

Table 1: Summary of the adverse drug reaction, severity and definitions used to select the multiple sclerosis cases and drug tolerant controls

| ADR | ADR Severity ^a | Case definition | Control definition |
|-------------------------|--|---|--|
| DMF-induced lymphopenia | Grade 3: Defined using the CTCAE as a 'severe or medically significant event' | 1. Normal baseline ^b ALC (≤ 6 months prior to DMF initiation) <i>and</i> 2. ≥ 1 laboratory test result with ALC $<500-200/\text{mm}^3$ or $<0.5-0.2 \times 10^9/\text{L}$ during DMF exposure (6, 7) | 1. Normal baseline ^b ALC (≤ 6 months prior to DMF initiation) <i>and</i> 2. Exposure to DMF for ≥ 1 year (5) <i>and</i> 3. ≥ 1 ALC test performed during treatment, with all results within the normal range ^b |

ADR: Adverse drug reaction, DMF: dimethyl fumarate, ALC: absolute lymphocyte counts.

^aGraded by the Common Terminology Criteria for Adverse Events (CTCAE) (v4.03) (6).

^bNormal range defined by the testing laboratory.

For the discovery stage, we require 156 patients (52 cases and 104 controls) to have sufficient power (80%) to identify a genomic variant (minor allele frequency > 0.15) with a clinically

1
2
3 significant effect size (odds ratio > 5.0) and application of the National Human Genome
4 Research Institute genome wide association study catalog threshold of $p < 1.0 \times 10^{-5}$ (15). The
5 sample size estimate is dependent upon the expected minor allele frequency of the genomic
6 variant. Given that there is no prior data from previous pharmacogenomics studies with DMF, a
7 minor allele frequency of 0.15 was used, as estimated by a previous pharmacogenomic study of
8 ADRs in MS (34). Sample size estimation was performed using Quanto (v.1.2.4) (16).
9
10
11
12
13
14
15
16
17

18 **Ethics, consent and permissions**

19
20 The University of British Columbia Clinical Research Ethics Board, and the Vancouver Coastal
21 Health Research Institute have approved this study protocol (H16-01927), which includes
22 written informed consent from all participants.
23
24
25
26
27

28 **Collection of saliva, genotyping and fine mapping**

29
30 A saliva sample will be obtained from patients, either during their clinic visit or collected at home
31 and returned via mail, with Oragene® collection tubes (DNA Genotek, Ottawa, Canada). DNA
32 will be extracted from saliva with the QIAmp DNA purification system (Qiagen, Hilden,
33 Germany) and subsequently quantified using the Quanti-iT PicoGreen assay (Invitrogen,
34 Carlsbad, USA). DNA samples will be stored at -20°C until all samples have been collected.
35
36
37
38
39
40
41
42

43 Samples will be processed with the Illumina Tecan Freedom EVO 150 and scanned on the
44 Illumina HiScan System (Illumina, San Diego, USA). Every set of 96 samples will include a
45 negative (1x Tris-EDTA buffer) and positive control. Samples will be genotyped using a
46 genome-wide genotyping array. We propose a hypothesis-free, genome-wide approach for the
47 identification of potential pharmacogenomic biomarkers related to this ADR. Rationale for this
48 approach stems from the dearth of literature on the genetic basis of drug-induced lymphopenia,
49 including no relevant pharmacogenomic studies with DMF. Moreover, as the exact mechanism
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of DMF-lymphopenia is undefined, it is impractical to predict which genes are involved in this
4
5 ADR. In the event that validated pharmacogenomic markers of drug-induced lymphopenia are
6
7 available at the time of genotyping, we will consider these in the current study.
8
9

10
11
12 For quality control purposes, genomic variants will be excluded with call rates <90%, a minor
13
14 allele frequency <1%, or those deviating from the Hardy-Weinberg equilibrium genotype
15
16 distribution ($p < 1.0 \times 10^{-5}$ in controls). Individual samples will also be excluded with call rates
17
18 <95%, and those cryptically related to other samples, or if the individual's sex according to the
19
20 genotyping is discordant with that recorded in the medical records.
21
22
23
24
25
26

27 We will perform linkage disequilibrium analyses (r^2 and D') using the 1000 Genomes CEU
28
29 population (Utah residents with Northern and Western European ancestry)
30
31 (<http://www.1000genomes.org>) and other populations, as appropriate. Haplotypes and
32
33 haplotype blocks will be calculated using CEU 1000 Genomes population as described (17).
34
35 Haplotype analyses will be implemented using Golden Helix SNP and Variation Suite (v.8.4,
36
37 Bozeman, USA).
38
39
40
41
42
43

44 Fine mapping and imputation will be performed to uncover putative causal variants. We will
45
46 perform genetic fine mapping analysis by genotype imputation of additional SNPs not present
47
48 on the genotyping platform using BEAGLE 4.0 with LD and haplotype information from 1000
49
50 Genomes (Phase 3) as the reference population (18, 19). We will impute additional variants on
51
52 the chromosome region (+/- 500 kb) containing any significant variants identified during the
53
54 discovery phase. Any significant variants within the imputed region will be assessed by means
55
56
57
58
59
60

1
2
3 of the Combined Annotation Dependent Depletion (CADD) framework (20) and corroboratory
4 evidence regarding the function of any associated variants will be explored from the literature.
5
6 The quality control metric (BEAGLE allelic R^2) will be calculated for all imputed SNPs, and will
7
8 include SNPs with an $R^2 \geq 0.5$ for analysis.
9
10

11
12
13 Given the association between specific human leukocyte antigen (HLA) alleles and a first-line
14 disease modifying therapy for MS, interferon-beta (21-23), we will also investigate whether an
15 association between DMF-induced lymphopenia and specific HLA alleles exist. We will directly
16
17 type *HLA-DRB1*15:01*, in addition to utilizing the HLA-specific imputation program, SNP2HLA
18
19 (24), to determine the specific HLA alleles of the individuals.
20
21
22
23
24
25

26
27 The genotyping calls of any significant variants from the genome-wide array, or those prioritized
28
29 by fine mapping, will be validated by TaqMan[®] genotyping assay (ThermoFisher Scientific,
30
31 Waltham, USA).
32
33
34
35

36 **Replication of findings**

37
38 We will seek to replicate any variants that reach the pre-determined threshold in this initial
39
40 cohort in an independent replication cohort within the Canadian Network of MS Clinics
41
42 (www.cnmsc.ca). All participant inclusion and exclusion criteria will match that of the criteria
43
44 utilized in the discovery cohort.
45
46
47
48

49 **Data management**

50
51 The principal investigator (HT) and the study team will manage all the patient data for this study.
52
53 All data will be stored on a secure server, on a password-protected computer, located at the
54
55 University of British Columbia, Faculty of Medicine.
56
57
58
59

Statistical analyses

Clinical and demographic factors will be compared between cases and controls. Categorical variables will be summarized by frequency (percent) and analyzed using either parametric (Chi-square test) or non-parametric tests (Fisher's exact test). Continuous variables will be summarized by describing mean (standard deviation) or median (interquartile range) and analyzed using the appropriate parametric (unpaired Student *t*-test) or non-parametric test (Mann-Whitney *U* test). Genomic ancestry will be ascertained by means of principal components analysis (EIGENSTRAT method) (25) utilizing the genotyping data and the 1000 Genomes Project reference data (18).

Differences in genotype and allele frequencies between cases and controls will be tested using logistic regression, with DMF-induced lymphopenia as the outcome. The logistic regression model will use an additive genetic model to identify associations since this model has been used previously to detect significant genetic differences associated with cases of adverse drug reactions (26, 27). In addition, the additive model is the most common genetic association test in which the underlying genetic model is unknown (28). The regression analyses will be adjusted for any relevant characteristics, such as sex, age, genetic ancestry or previous disease modifying therapy exposure (7). To examine evidence of additional genetic associations with the adverse drug reaction in the imputed region, the same analysis and models utilized in the initial analysis will be applied.

For the genomic association analyses, the threshold to indicate variants that will require replication will be $p < 1.0 \times 10^{-5}$ (15). During the replication stage of the genomic analysis, we will employ a Bonferroni corrected $p < 0.05/n$ (n = number of significant SNPs from the discovery phase). We will include any genetic variants reaching the predetermined significance threshold

1
2
3 into the logistic regression model and adjust for potential confounders. Golden Helix SNP and
4 Variation Suite (v.8.4, Bozeman, USA) and IBM SPSS (v.23, Armonk, USA) will be used to
5 conduct the statistical analyses. Visual plots (Manhattan and regional association plots) will be
6 generated using Golden Helix and LocusZoom (29).
7
8
9
10

11 12 13 **Dissemination**

14 Findings will be disseminated via various avenues, including at scientific conferences, via
15 podcasts (targeted to healthcare professionals, patients and the general public), through patient
16 engagement and other outreach events, written lay summaries for all participants, and formal
17 publication in peer-reviewed scientific journals.
18
19
20
21
22
23
24
25
26

27 **Discussion**

28 ADRs present a significant burden to global health care systems. In the United Kingdom alone,
29 ADRs were estimated to cost the National Health Service £466 million (US\$847 million) in 2002
30 (2). A more recent Swedish study reported the overall annual direct cost of adverse drug events
31 as US\$21 million per 100,000 habitants, including the costs of diagnosing, monitoring or treating
32 the events (30). Neither the financial costs nor the morbidity and mortality rates associated with
33 ADRs to the MS disease modifying therapies are fully known as yet; this is despite the
34 ubiquitous use of these therapies. Given the clinical importance of ADRs, it is highly desirable to
35 minimize their occurrence. One approach to minimizing ADRs is through the discovery and
36 implementation of pharmacogenomic biomarkers; an example of the utility of this approach is
37 demonstrated by the now commonly accepted clinical practice of testing for the *HLA-B*57:01*
38 allele in HIV-infected persons to prevent abacavir induced hypersensitivity (31).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Our protocol, which is aimed here at discovering biomarkers associated with DMF-lymphopenia,
4 is readily adaptable to the search for genomic markers of other ADRs associated with the MS
5 disease modifying therapies (e.g. alemtuzumab induced immune thrombocytopenia). There are
6 several key considerations when conducting pharmacogenomic studies of serious ADRs (32).
7 Arguably one of the most important is the thorough phenotyping of cases and controls, as poor
8 characterization contributes to the lack of replication between studies (8). We have proposed to
9 investigate a phenotype that is based on an objective laboratory measurement (the absolute
10 lymphocyte counts); this may facilitate replication in future studies. A genome-wide, hypothesis-
11 free method, as proposed here, could be considered an ideal approach to identify
12 pharmacogenomic biomarkers associated with an ADR because the mechanism of action of
13 DMF is unclear (33), making it difficult to pre-specify or hypothesize which genes might be
14 involved in the ADR. Other important considerations when designing pharmacogenomic studies
15 of serious adverse drug reactions include the appropriate sourcing of a second cohort to
16 replicate the findings from the discovery stage; a multi-center collaboration is being sought
17 through the Canadian Network of MS clinics (www.cnmsc.ca); this has been successfully
18 achieved in a prior study (34). Such collaboration can also serve to demonstrate the
19 generalizability of findings across multiple sites.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 The disease modifying therapy options that are available for people with MS have increased
42 substantially over the last decade. This rise in therapeutic choices has provided many benefits,
43 including non-injectable options and, for the newer therapies, increased efficacy over the
44 previous MS disease modifying therapies (5, 35, 36). However, serious ADRs are associated
45 with these newer disease modifying therapies, and there are currently few means of predicting
46 whom they might affect. If pharmacogenomic biomarkers can be identified by the methods
47 proposed here, this would offer a 'precision medicine' approach to managing MS drug
48 treatments by facilitating choice of optimal disease modifying therapy or by tailoring safety
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 monitoring. Ultimately, the incorporation of pharmacogenomic biomarkers into the complex
4 therapeutic decision-making process would benefit MS patients and healthcare providers.
5
6
7

8
9 Acknowledgements: Not applicable.

10 Author Contributions: KK, EK and HT contributed to the concept and design of the study, and
11 drafting of the article. All authors reviewed, commented and approved the final manuscript.

12 Funding: This work was supported by the Canadian Institutes of Health Research (CIHR) –
13 Drug Safety and Effectiveness Network (British Columbia site PI: Tremlett).
14

15 Competing interests: There are no conflicts related to this work. KK, EK, RC, and SB have no
16 competing interests to declare. AT has received grant support from Hoffman la Roche and
17 Sanofi Genzyme; steering committee membership for Hoffman la Roche; consultancy for
18 Biogen, Chugai, EMD Serono, Hoffman la Roche, Medimmune, Sanofi Genzyme, and Teva
19 Neuroscience. RAM has conducted clinical trials for Sanofi-Aventis and receives research
20 funding from CIHR, the National MS Society, the MS Society of Canada, the MS Scientific
21 Research Foundation, Research Manitoba, and the Waugh Family Chair in Multiple Sclerosis.
22 CJDR receives funding support from the Canadian Institutes of Health Research, Canadian
23 Foundation for Innovation, Canadian Hearing Foundation, BC Children's Hospital Foundation,
24 BC Children's Hospital Research Canadian Gene Cure Foundation, Teva Pharmaceutical
25 Industries Inc., Genome BC, and the CIHR Drug Safety & Effectiveness Network. BC currently
26 receives research funding from the Canadian Institutes of Health Research, Genome Canada,
27 Genome British Columbia and BC Children's Hospital Research (Vancouver, Canada) and has
28 previously held matching funds support for Genome Canada funding from Pfizer Canada
29 (unrestricted). HT has received speaker honoraria and/or travel expenses to attend conferences
30 in the last five years from the Consortium of MS Centres (2013), National MS Society (2012,
31 2014, 2016), ECTRIMS (2012-2016), the Chesapeake Health Education Program, US Veterans
32 Affairs (2012), Novartis Canada (2012), Biogen Idec (2014), AAN (2013-2016). All speaker
33 honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by
34 her research group.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 References

- 51
52 1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients:
53 a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5.
54
55
56
57
58
59
60

2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ*. 2004;329(7456):15-9.
3. Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. *N Engl J Med*. 2015;372(15):1476-8.
4. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. *N Engl J Med*. 2013;368(17):1658-9.
5. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. *N Engl J Med*. 2012;367(12):1087-97.
6. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) 2010, Version 4.03. Accessed 1 July 2016. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
7. Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. *MSJ Exp Transl Clin*. 2015;1.
8. Pirmohamed M. Pharmacogenetics: past, present and future. *Drug Disc Today*. 2011;16(19-20):852-61.
9. Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, et al. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. *Pharmacoepidemiol Drug Saf*. 2009;18(8):713-21.
10. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann Neurol*. 1983;13(3):227-31.
11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol*. 2001;50(1):121-7.
12. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol*. 2005;58(6):840-6.
13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*. 2011;69(2):292-302.
14. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther*. 1981;30(2):239-45.
15. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res*. 2014;42(Database issue):D1001-6.
16. Gauderman WJ MJ. QUANTO version 1.2.4 2006. Accessed on 1 April 2016. Available at: <http://hydra.usc.edu/gxe>.
17. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. *Science*. 2002;296(5576):2225-9.
18. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. *Nature*. 2015;526(7571):68-74.

19. Browning BL, Browning SR. Genotype Imputation with Millions of Reference Samples. *Am J Hum Genet.* 2016;98(1):116-26.
20. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet.* 2014;46(3):310-5.
21. Mazdeh M, Taheri M, Sayad A, Bahram S, Omrani MD, Movafagh A, et al. HLA genes as modifiers of response to IFN-beta-1a therapy in relapsing-remitting multiple sclerosis. *Pharmacogenomics.* 2016;17(5):489-98.
22. Nunez C, Cenit MC, Alvarez-Lafuente R, Rio J, Fernandez-Arquero M, Arroyo R, et al. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-beta therapy in multiple sclerosis. *J Med Genet.* 2014;51(6):395-400.
23. Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima I, Brynedal B, et al. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. *PloS one.* 2014;9(3):e90479.
24. Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS, et al. Imputing amino acid polymorphisms in human leukocyte antigens. *PloS one.* 2013;8(6):e64683.
25. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet.* 2006;38(8):904-9.
26. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet.* 2009;41(7):816-9.
27. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology.* 2011;141(1):338-47.
28. Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT. Basic statistical analysis in genetic case-control studies. *Nat Protoc.* 2011;6(2):121-33.
29. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics.* 2010;26(18):2336-7.
30. Gyllensten H, Hakkarainen KM, Hagg S, Carlsten A, Petzold M, Rehnberg C, et al. Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adults. *PloS one.* 2014;9(3):e92061.
31. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med.* 2008;358(6):568-79.
32. Kowalec K, Carleton B, Tremlett H. The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. *Mult Scler Rel Disord.* 2013;2(3):183-92.
33. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain.* 2011;134(Pt 3):678-92.

- 1
2
3 34. Kowalec K, Wright GEB, Drögemöller B, Aminkeng F, Bhavsar AP, Kingwell E, et al. Genome-
4 wide scan identifies association between an interferon regulatory factor-related variant and interferon-
5 beta induced liver injury in multiple sclerosis patients. *Mult Scler J*. 2016;22(S3):828-83.
6
7 35. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or
8 intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med*. 2010;362(5):402-15.
9
10 36. Vermersch P, Czlolkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al.
11 Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a
12 randomised, controlled phase 3 trial. *Mult Scler*. 2014;20(6):705-16.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60